key: cord-0820233-ensd6lfx
authors: Fajar, Jonny Karunia; Wibowo, Bogi Pratomo; Dewi, Gheavita Chandra; Rahmadi, Adi Putra; Kusuma, Meike Tiya
title: Does MAFLD really increase the severity of COVID-19?
date: 2020-11-11
journal: Dig Liver Dis
DOI: 10.1016/j.dld.2020.10.042
sha: e2bcc6b6664ee16224cb068bc79702fa0c382766
doc_id: 820233
cord_uid: ensd6lfx

nan

We found that the study has several limitations that should be clarified. First, the article includes several letters to the Editor. At least four 2-5 out of six papers 2-7 are letters to the Editor. Although the Newcastle-Ottawa scale (NOS) was used to assess the quality of the included papers, which had moderate to high quality, the vast majority of meta-analysis studies excluded letters to the Editor. Referring to guideline from Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), 8 reviews, commentaries, and letters to the Editor should be excluded. Nevertheless, since they have moderate-high quality based on the NOS criteria, these articles might be tolerable for inclusion in the meta-analysis. Second, two 2, 4 out of six papers 2-7 do not provide sufficient data for meta-analysis. The data of MAFLD prevalence in both severe and mild-moderate COVID-19 are insufficient to calculate the correlation and effect estimates. In the study by Zou et al 2 for example, the data are presented as total cases of severe COVID-19 and total cases of MAFLD. The data on how many MAFLD patients developed severe and mild -moderate COVID-19 were not presented. Therefore, the calculation of cumulative effect estimates, and the correlation was impossible to perform, and this article should be excluded. Moreover, in the study by Targher et al, 4 the available data are only the number of MAFLD patients with neutrophil-tolymphocyte ratio (NLR) ≤ 2.8 and NLR > 2.8. NLR is not the indicator of COVID-19 severity. The indicators of COVID-19 severity include any of the following criteria: respiratory distress (RR ≥ 30/min), oxygen saturation ≤ 93% at rest, and arterial partial pressure of oxygen (PaO2) / fraction of inspiration O2 (FiO2) ≤ 300 mnHg. 9 Therefore, we consider that this article does not meet the criteria to define severe COVID-19 and should be excluded. We re-analyzed the data after excluding those two papers and found that patients with MAFLD had a 6-fold higher risk of developing severe COVID-19 compared to those without MAFLD,(OR: 6.66; 95%CI: 2.84, 15.64) (Fig 1) . Although our analysis is consistent with Pan et al 1 , our analysis highlights a higher risk. 

The authors received no financial support for the research, authorship, and/or publication of this article.

None of the authors has any conflicts to declare. 

Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis. Digestive and Liver Disease 2020

Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19

Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients

Metabolic-associated fatty liver disease is associated with severity of COVID-19

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Coronavirus Disease 2019 (COVID-19): A Perspective from China

We thank to International COVID-19 Project: Indonesia Chapter & LPDP Republik Indonesia.